Thank You!
Your details have been successfully submitted 😍.
C-level from Big Pharma, Biotech, Academia, Regulatory, VC
Small Molecules
Exploring novel scaffolds, fragment-based drug design, and hybrid modalities in modern small molecule discovery.
Combining crystallography, modeling, and machine learning to accelerate hit-to-lead progression.
Emerging strategies to drug targets once considered inaccessible, including protein-protein interactions and RNA-binding proteins.
Biologics + Biosimilars
Innovative developments in biologic drug platforms including monoclonal antibodies, antibody-drug conjugates, and fusion proteins.
Key insights into biosimilar development pathways, regulatory trends, and analytical characterization.
Addressing formulation challenges, delivery systems, and bioavailability for next-gen biologics.
Snacks + Meet-the-scientist Corners
From Code to Cure: AI in Drug Discovery
Exploring how machine learning enhances virtual screening, compound libraries, and hit prioritization.
Leveraging generative models to create novel chemical entities with drug-like properties.
Using AI to uncover and validate new biological targets with greater speed and precision.
How AI tools guide lead optimization by predicting ADMET properties and reducing experimental cycles.
Harnessing complex biological data through AI to enable precision discovery and pathway analysis.
On-site Reception + Music
Lounge Opens Early; Summary of Day 1 Pitches + Meetings
More 3-min Startup Pitches, Networking Breaks
Protein Degradation & Molecular Glues
RNA-based Therapeutics
Final Networking Break, Feedback Corner